Sars-CoV-2 (COVID-19)? A New Discovery that Helps the Body Make Its Own Igg Efficiently

The purpose of this research is to develop a new formulation that neutralizes spike glycoproteins and destroys the shell containing these spikes, including the core containing the genetic material of the virus. Spike glycoproteins are the cause of disseminated intravascular coagulation, damage to organ tissues, create a violent inflammatory response when foreign objects enter the body, cause necrosis of organ tissues and lead to death or left with severe sequelae after infection with Sars-CoV-2. The product is effective in eliminating viruses early, not allowing them to have enough time to multiply. This new treatment formulation does not depend on the mutated forms of Sars-CoV-2. The formulation should be applied early when exposure is suspected or in high-risk areas to prevent and reduce mortality as well as reduce health damage to patients after infection. The product is safe, 100% effective, and has been retrospectively accounted for in individuals diagnosed with natural or acquired immunodeficiency who have been identified with underlying diseases.

Observationally, all of the patients who had previously used the ingredients in the formulation for various therapeutic purposes had no known cases of Sars-CoV-2 infection, nor when they are living in an epidemic area.

All of these patients, when they had close contact with their infected member in the family, were safe and not infected, while all the rest of their family members were infected to some different degree. The formulation helps the body make its own IgG efficiently, easily eliminating Sars-CoV-2.